Protocol summary
-
Study aim
-
Determining the effect of capsules containing rice bran oil and fucoxanthin on lipid profile, inflammatory factors and clinical cardiovascular indicators in patients with coronary heart disease.
-
Design
-
Clinical trial with a control group, with parallel groups, double-blind, randomized, phase 3 on 50 patients. The website http://www.randomization.com will be used for randomization.
-
Settings and conduct
-
Patients referred to Heshmat hospital, Rasht were randomly allocated into two intervention groups ( receiving a standard diet containing olive oil as the main fat source + consuming three capsules of rice bran oil and fucoxanthin daily) and control (receiving a standard diet containing olive oil as the main fat source + consuming three placebo capsules) will be included in the study. This study is double-blind and since the capsules containing rice bran oil and fucoxanthin and placebo will be completely similar to each other, and the patients receiving and the researchers providing the supplements will be blinded to the type of supplement.
-
Participants/Inclusion and exclusion criteria
-
The inclusion criteria: coronary artery blockage, no use of supplements, no history of kidney disease, no current consumption of alcohol.
The exclusion criteria: change in the treatment plan and the type of effective drugs used in the study, unwillingness to continue the study or any dissatisfaction with the taste of the oil, etc.
-
Intervention groups
-
Intervention group: receiving standard diet + consuming three capsules of rice bran oil and fucoxanthin daily for 12 weeks
Control group: receiving a standard diet + taking three placebo capsules daily for 12 weeks
-
Main outcome variables
-
lipid profile, fasting blood sugar level, inflammatory and antioxidant markers, and left ventricular ejection fraction
General information
-
Reason for update
-
Due to observing beneficial effects and no side effects from administering 30 grams per day of rice bran oil and 1 gram per day of rice bran oil capsules in previous clinical trial projects of the current group (whose articles have been published), it has been decided in this study to increase the amount of oil to 3 grams per day.
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20240717062445N1
Registration date:
2024-07-23, 1403/05/02
Registration timing:
prospective
Last update:
2025-01-25, 1403/11/06
Update count:
1
-
Registration date
-
2024-07-23, 1403/05/02
-
Registrant information
-
-
Recruitment status
-
recruiting
-
Funding source
-
-
Expected recruitment start date
-
2025-02-27, 1403/12/09
-
Expected recruitment end date
-
2026-02-28, 1404/12/09
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Effects of a supplement containing rice bran oil and fucoxanthin on lipid profile, inflammatory indicators, and clinical and biochemical cardiovascular parameters in patients with coronary artery disease: A randomized clinical trial
-
Public title
-
Capsules containing rice bran oil and fucoxanthin in patients with coronary heart disease
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Age range 20 to 70 years
Not using vitamin and mineral supplements, antioxidants, fiber supplements, omega-3
No history of kidney disease, no current alcohol consumption
Coronary artery occlusion diagnosed by angiography by a cardiologist.
No current consumption of alcoholic beverages
Exclusion criteria:
Changes in the patient's coronary disease treatment plan during the study
Changing the type of drugs used, effective factors studied
Creating any kind of dissatisfaction in the field of oil taste and...
-
Age
-
From 20 years old to 70 years old
-
Gender
-
Both
-
Phase
-
3
-
Groups that have been masked
-
-
Sample size
-
Target sample size:
50
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
The method of sampling and randomization of this two parallel double-blind clinical trial study, will be using the stratified block randomization method. At first, the participants will be classified into two groups according to their age (20 to 45 years and between 45 to 70 years), and then each person will randomly assigned to the intervention or control group using blocks of 4 randomly at a ratio of 1:1. One of the letters A or B will be assigned to each group.For randomization, the website http://www.randomization.com/ will be used. The list of codes obtained from this website will be provided to the researchers, and every referring patient who meets the inclusion criteria and does not meet the exclusion criteria and is willing to participate in the research, is first entered in the desired age group and in order Based on the assigned code, A or B enters the plan
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
Since the capsules containing rice bran oil and fucoxanthin and placebo have been tried to be completely similar to each other due to the similarity in taste, aroma and smell, the patients receiving and the researchers providing the supplements of the type of supplement that each participant receives will not find awareness.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2024-06-26, 1403/04/06
-
Ethics committee reference number
-
IR.GUMS.REC.1403.154
Health conditions studied
1
-
Description of health condition studied
-
Coronary artery disease
-
ICD-10 code
-
I25.1
-
ICD-10 code description
-
Atherosclerotic heart disease of native coronary artery
Primary outcomes
1
-
Description
-
Serum lipid profile levels (triglycerides, total cholesterol, LDL-C and HDL-C)
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
BT2000 device
2
-
Description
-
Fasting blood sugar
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
BT2000 device
3
-
Description
-
Serum insulin
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
BT2000 device
4
-
Description
-
Glycosylated hemoglobin
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
ELISA device
5
-
Description
-
Erythrocyte sedimentation rate
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
ELISA device
6
-
Description
-
Glutathione peroxidase activity
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
ELISA device
7
-
Description
-
Glutathione reductase activity
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
ELISA device
8
-
Description
-
Vitamin E
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
ELISA device
9
-
Description
-
HS - C-reactive protein
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
ELISA device
Secondary outcomes
1
-
Description
-
Mean systolic and diastolic blood pressure
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
Pressure indicator
2
-
Description
-
Body mass index
-
Timepoint
-
At the beginning of the study and 12 weeks later
-
Method of measurement
-
Centimeter and scales
Intervention groups
1
-
Description
-
Intervention group: receiving a standard diet containing olive oil as the main fat source + consuming three capsules of rice bran oil produced by Giltaz company and fucoxanthin produced by Danesh Bonyan Algae Bank company (daily) for 12 weeks with lunch
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: receiving a standard diet containing olive oil as the main fat source+ taking three placebo capsules produced by Barij Essence Company for 12 weeks along with lunch. The placebo capsule contains paraffin. The placebo will be completely similar to the capsule of the intervention group in terms of shape, color and smell, and they will be placed in cans of the same shape and color.
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Rasht University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
No - There is not a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available